From MarketWatch Retirement:
Eli Lilly’s positive results from a seen as ‘potentially very important.’ Eli Lilly’s positive Phase 3 trial showed that the drug donanemab “significantly slowed cognitive and functional decline” in patients with early symptomatic Alzheimer’s disease.
What happens to if no debt-ceiling deal is reached? Failure...